Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in HbA1c achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin 5 mg or saxagliptin 2.5 mg compared to placebo in pediatric T2DM subjects with HbA1c levels of 6.5 to 10.5% on diet and exercise and metformin (IR or XR), insulin, or metformin (IR or XR) plus insulin.
Principal Investigator | Marcel Twahirwa, MD |
Co-PI | Luis Cantu Jr. |
Sponsor | AstraZeneca |
Type of Trial | Interventional |